JPRN-jRCT2080221796未知1 期
A Phase 1 Study of veliparib (ABT-888) in Combination with Carboplatin/Paclitaxel in Japanese Subjects with solid tumors
适应症
试验速览
- 阶段
- 1 期
- 发起方
- AbbVie GK
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Patients must have histologically or cytologically confirmed malignant solid tumor.
- •- Patients who are amenable to standard combination chemotherapy of carboplatin and paclitaxel.
- •- Patients should have received less than or equal to 1 prior chemotherapy regimens for advanced stage disease.
- •- Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.
- •- Patients must have normal organ and marrow function.
排除标准
- •- Patients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C)
- •prior to entering the study or the adverse events due to agents administered more than 3 weeks earlier have not recovered to less than grade 2.
- •- Known history of allergic reactions to carboplatin or cremophor-paclitaxel.
- •- Patients who have previously received a poly(ADP-ribose) polymerase (PARP) inhibitor.
- •- Uncontrolled intercurrent illness including, but not limited to, ongoing or active systemic infection requiring treatment, symptomatic congestive heart failure, angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- •- History of seizure disorder.
- •- Hepatitis B surface antigen (HBsAg) positive, Hepatitis C virus (HCV) antibody positive or Human
- •immunodeficiency virus (HIV)-positive patients.
研究者
相似试验
已完成
1 期
A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid TumorsSolid TumorsNCT01617928AbbVie (prior sponsor, Abbott)12
撤回
1 期
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine TumorFunctional Pancreatic Neuroendocrine TumorMalignant SomatostatinomaMetastatic Adrenal Gland PheochromocytomaMetastatic Carcinoid TumorMultiple Endocrine Neoplasia Type 2AMultiple Endocrine Neoplasia Type 2BMultiple Endocrine Neoplasia Type 1Merkel Cell CarcinomaNon-Functional Pancreatic Neuroendocrine TumorPancreatic GlucagonomaPancreatic InsulinomaRecurrent Adrenal Cortex CarcinomaNeuroendocrine NeoplasmRecurrent Adrenal Gland PheochromocytomaRecurrent Merkel Cell CarcinomaSomatostatin-Producing Neuroendocrine TumorStage III Adrenal Cortex CarcinomaStage III Thyroid Gland Medullary CarcinomaStage IIIA Merkel Cell CarcinomaStage IIIB Merkel Cell CarcinomaStage IV Adrenal Cortex CarcinomaStage IV Merkel Cell CarcinomaStage IVA Thyroid Gland Medullary CarcinomaStage IVB Thyroid Gland Medullary CarcinomaStage IVC Thyroid Gland Medullary CarcinomaThymic Carcinoid TumorVIP-Producing Neuroendocrine TumorWell Differentiated Adrenal Cortex CarcinomaZollinger Ellison SyndromeNCT02831179Vanderbilt-Ingram Cancer Center
已完成
1 期
A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid TumorsAdvanced Solid TumorsNCT01063816AbbVie (prior sponsor, Abbott)79
已完成
1 期
Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal CancerAdult Solid NeoplasmPeritoneal CarcinomatosisRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaNCT01264432National Cancer Institute (NCI)34
已完成
1 期
Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Pancreatic CancerPancreatic CancerNCT01908478Cedars-Sinai Medical Center34